Viking Therapeutics (VKTX) Cash from Operations (2014 - 2026)
Viking Therapeutics (VKTX) posted Cash from Operations of 125172000.0 for Q2 2026, down 9.82% sequentially from 113976000.0 in Q1 2026, and down 165.98% YoY from 189717213.91 in Q2 2025.
Powered by 
Analysis
Viking Therapeutics (VKTX) Cash from Operations (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Cash from Operations for 13 years, with the latest figure at 125172000.0 in Q2 2026.
- Quarterly Cash from Operations fell 165.98% year-over-year to 125172000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 418441000.0 (down 174.32% YoY) and the FY2025 annual result came in at 278685000.0, down 217.45% from the prior year.
- Cash from Operations eased to 125172000.0 in Q2 2026 per VKTX's latest filing, from 113976000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 6134000.0 in Q1 2024 and troughed at 125172000.0 in Q2 2026.
- A 5-year average of 40410888.89 and a median of 23302500.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 75.11% in 2024, then plunged 753.13% in 2025.
- Over 5 years, Cash from Operations stood at 10926000.0 in 2022, then sank by 61.45% to 17640000.0 in 2023, then slumped by 76.76% to 31181000.0 in 2024, then plunged by 173.53% to 85290000.0 in 2025, then sank by 46.76% to 125172000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 125172000.0, 113976000.0, and 85290000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Viking Therapeutics | 4.06 Bn | 4.06 Bn | - | -125.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -125.17 Mn |
| Mar 31, 2026 | -113.98 Mn |
| Dec 31, 2025 | -85.29 Mn |
| Sep 30, 2025 | -94.00 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Mar 31, 2025 | -52.33 Mn |
| Dec 31, 2024 | -31.18 Mn |
| Sep 30, 2024 | -21.96 Mn |
| Jun 30, 2024 | -28.51 Mn |
| Mar 31, 2024 | -6.13 Mn |
| Dec 31, 2023 | -17.64 Mn |
| Sep 30, 2023 | -19.66 Mn |
| Jun 30, 2023 | -11.44 Mn |
| Mar 31, 2023 | -24.64 Mn |
| Dec 31, 2022 | -10.93 Mn |
| Sep 30, 2022 | -13.50 Mn |
| Jun 30, 2022 | -13.44 Mn |
| Mar 31, 2022 | -10.53 Mn |
| Dec 31, 2021 | -12.35 Mn |
| Sep 30, 2021 | -10.93 Mn |